Lymphocyte subset expression and serum concentrations of PD-1/PD-L1 in sepsis - pilot study.

ABSTRACT:

Background

Sepsis remains a major cause of mortality in critical care, for which specific treatments are lacking. The dysregulated response to infection seen in sepsis includes features of lymphocyte dysfunction and exhaustion, suggesting that immune-stimulatory therapy may improve outcomes in certain patient groups. Monoclonal antibodies targeting checkpoint molecules, such as programmed-death 1 protein (PD-1) and its ligand PD-L1, have shown success in stimulating the immune response in patients with cancer, and are being considered for future sepsis trials. The aims of this pilot study were to compare lymphocyte subset expression of PD-1 and its ligands between patients with sepsis and controls; to characterize serum levels of PD-1 and PD-L1 in patients with sepsis and controls,

SUBMITTER: Wilson JK 

PROVIDER: S-EPMC5902875 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature